Dynamic monitoring of serum liver function indexes in patients with COVID-19

被引:0
|
作者
HaoLin [1 ]
Ling-JieWu [2 ]
Shun-QiGuo [3 ]
Rui-LieChen [2 ]
Jing-RuFan [3 ]
BinKe [4 ]
Ze-QunPan [5 ]
机构
[1] DepartmentofGastroenterology,ShantouCentralHospital
[2] DepartmentofInfectiousDisease,ShantouCentralHospital
[3] DepartmentofEmergency,ShantouCentralHospital
[4] DepartmentofUltrasonography,ShantouCentralHospital
[5] DepartmentofPediatrics,ShantouCentralHospital
关键词
D O I
暂无
中图分类号
R563.1 [肺炎];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Some patients with the novel 2019 coronavirus disease(COVID-19) display elevated liver enzymes. Some antiviral drugs that can be used against COVID-19 are associated with a risk of hepatotoxicity.AIM To analyze the clinical significance of the dynamic monitoring of the liver function of patients with COVID-19.METHODS This was a retrospective study of patients diagnosed with COVID-19 in January and February 2020 at the Department of Infection, Shantou Central Hospital. The exclusion criteria for all patients were:(1) History of chronic liver disease;(2) History of kidney disease;(3) History of coronary heart disease;(4) History of malignancy; or(5) History of diabetes. The serum levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST), γ-glutamyltransferase, and total bilirubin of patients with COVID-19 were measured on days 1, 3, 7 and 14 after admission, and compared to non-COVID-19 patents.RESULTS Twelve patients with COVID-19(seven men and five women) and twelve controls(eight men and four women) were included. There were one, two, and nine patients with severe, mild, and moderate COVID-19, respectively. There were no differences in age and sex between the two groups(both P > 0.05). No significant differences were found in albumin, ALT, AST, γ-glutamyltransferase, or total bilirubin between the controls and the patients with COVID-19 on day 1 of hospitalization(all P > 0.05). Serum albumin showed a decreasing trend from days 0 to 7 of hospitalization, reaching the lowest level on day 7. Total bilirubin was higher on day 3 than on day 7. ALT, AST, and γ-glutamyltransferase did not change significantly over time. The severe patient was observed to have ALT levels of 67 U/L and AST levels of 75 U/L on day 7, ALT of 71 U/L and AST of 35 U/L on day 14, and ALT of 210 U/L and AST of 123 U/L on day 21.CONCLUSION Changes in serum liver function indicators are not obvious in the early stage of COVID-19, but clinically significant changes might be observed in severe COVID-19.
引用
收藏
页码:1554 / 1562
页数:9
相关论文
共 50 条
  • [21] LIVER FUNCTION ABNORMALITIES AND MORTALITY IN PATIENTS WITH CORONAVIRUS DISEASE 2019 (COVID-19)
    Suarez, Laura Suzanne
    Simms, Larnelle
    Dewaswala, Nakeya
    Gupta, Kapil
    Dziadkowiec, Karolina
    Stawinski, Peter
    Aboulenain, Samar
    Torrres, Pedro
    Bhopalwala, Huzefa
    Tuarez, Fergie Ramos
    Pino, Jesus
    De Almeida, Kleper
    HEPATOLOGY, 2020, 72 : 285A - 285A
  • [22] Prognostic value of abnormal liver function test for hospitalized patients with COVID-19
    Mateu, Carlos Alventosa
    Benlloch, Salvador
    Diago, Moises
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2024, 47 (02): : 192 - 193
  • [23] Antiviral use in liver function abnormalities and Covid-19 patients: Serial cases
    Dewi, Intan Rizkia
    Maimunah, Ummi
    ANNALS OF MEDICINE AND SURGERY, 2022, 84
  • [24] Protective effects of COVID-19 vaccination on endothelial function of patients with COVID-19
    Lampsas, S.
    Oikonomou, E.
    Souvaliotis, N.
    Papamikroulis, G. A.
    Lytra, T.
    Sarantos, S.
    Mystakidi, V. C.
    Pantelidis, P.
    Kalogeras, K.
    Theofilis, P.
    Tsatsaragkou, A.
    Siasos, G.
    Tsioufis, C.
    Tousoulis, D.
    Vavuranakis, M.
    EUROPEAN HEART JOURNAL, 2022, 43 : 3048 - 3048
  • [25] Respiratory Monitoring at Bedside in COVID-19 Patients
    Giustivi, Davide
    Bottazzini, Francesco
    Belliato, Mirko
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [26] Monitoring of COVID-19 patients by telemedicine with telemonitoring
    Martinez-Garcia, M.
    Bal-Alvarado, M.
    Santos Guerra, F.
    Ares-Rico, R.
    Suarez-Gil, R.
    Rodriguez-Alvarez, A.
    Perez-Lopez, A.
    Casariego-Vales, E.
    REVISTA CLINICA ESPANOLA, 2020, 220 (08): : 472 - 479
  • [27] Dynamic Changes in Liver Function Tests and Their Correlation with Illness Severity and Mortality in Patients with COVID-19: A Retrospective Cohort Study
    Xu, Wei
    Huang, Chenlu
    Fei, Ling
    Li, Qiang
    Chen, Liang
    CLINICAL INTERVENTIONS IN AGING, 2021, 16 : 675 - 685
  • [28] Gastrointestinal and liver manifestations in patients with COVID-19
    Lee, I-Cheng
    Huo, Teh-Ia
    Huang, Yi-Hsiang
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (06) : 521 - 523
  • [29] Tocilizumab and liver injury in patients with COVID-19
    Serviddio, Gaetano
    Villani, Rosanna
    Stallone, Giovanni
    Scioscia, Giulia
    Foschino-Barbaro, Maria Pia
    Lacedonia, Donato
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [30] Liver transplantation in COVID-19 positive patients
    Raveh, Yehuda
    Simkins, Jacques
    Nicolau-Raducu, Ramona
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (05) : 1978 - 1978